Skip to main content
IVVD logo

IVVD · Invivyd, Inc.

Track IVVD — free
$0.72 +0.04 (+5.13%) At close · Aug 14
Market Cap
$212.49M
Shares
294.76M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.72 Open$0.69 Day$0.66–0.73 52W close$0.52–2.88 Avg vol 30d3.2M Short int27.8M · 9.4% float · 8.9d Short vol49% Last earningsAug 13, 2026 DataAug 2021–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Nov 26, 2026 Est · unconfirmed · in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Aug 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −54%
      below
      Price vs 50-day avg −8%
      below
      RSI (14) 52
      neutral
      MACD trend Positive
      52-week position 9%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −3%
      trailing
      6-month return −55%
      trailing
      YTD return −71%
      this year
      Relative strength −69%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +34 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.43% of float · ▼ -5.1% MoM · 8.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      125 holders — mid 3-yr range
      Squeeze score 61
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +110%
      Y/Y
      EPS growth +79%
      Y/Y
      Free cash flow $-58.3M
      Balance sheet $226.7M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 143%
      annualized · 1-yr
      Max drawdown −81%
      past year
      ATR 9.1%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 2 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −54% Bearish
      Price vs 50-day avg
      −8% Bearish
      RSI (14)
      52 Neutral
      MACD trend
      Positive Bullish
      52-week position
      9% Bearish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Distributing
      -11% holders QoQ · +34 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      9.43% of float · ▼ -5.1% MoM · 8.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      125 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $1 Now $1 · 9% Range high $3
      vs 200-day avg -54% vs 50-day avg -8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IVVD
      Invivyd, Inc.
      this stock
      $212.49M -70.8% +110.5% 9.4%
      ONC
      BeOne Medicines Ltd.
      $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      $52.94B +1.2% 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      125
      % held
      79.2%
      Net QoQ
      +6.1M sh
      Top holder
      Jupiter Topco LLC
      Held Float
      View
      Held by Funds
      Fund positions
      36
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      27.8M
      Days to cover
      8.9d
      Change
      -1.5M sh
      View
      Short Volume
      Short vol %
      49%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      296.9K
      Value
      $237.5K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      62.6%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $53.4M
      Net income (FY)
      $-52.5M
      EPS diluted
      $-0.30
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 13, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $103.0K
      Shares
      66.0K
      Filed
      Feb 17, 2026
      View
      Exempt Offerings
      Offering
      $23.7M
      Filed
      Nov 29, 2022
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      IVVD -2.6% -3.0% -55.2% +34.8% -70.8%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -3.0% -7.4% -69.0% +30.8% -84.7%
      Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 128 filings 125 filers Visit website Investor relations